Trial Profile
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Latozinemab (Primary)
- Indications Frontotemporal dementia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms INFRONT-3
- Sponsors Alector
- 07 Feb 2024 According to an Alector media release, trial achieved target enrollment in October 2023.
- 01 Nov 2023 Planned number of patients changed from 180 to 110.
- 01 Nov 2023 Planned End Date changed from 30 Dec 2023 to 11 Oct 2027.